Monocyte Activation Tests Market Scope And Analysis

Report Code : TIPRE00004912
Category : Medical Device

No. of Pages : 150

Buy Now

Monocyte Activation Tests Market Scope, Analysis, and Trends by 2030

Buy Now

Monocyte Activation Tests Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 65.17436 Million
Market Size by 2030	US$ 236.71417 Million
Global CAGR (2022 - 2030)	17.5%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Source PMBC and Cell Line By Products MAT Kits and Reagents By and Application Drug Development Vaccine Development Medical Devices
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Merck KGaA Darmstadt Germany and or its affiliates Charles River Laboratories International Inc Thermo Fisher Scientific Sanquin Lonza Group MAT Biotech Cellmade Laboratories Labor LS SE Co KG BD Biosciences

Regional Analysis

Based on region, the monocyte activation tests market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America captured the largest market share in 2022 and is expected to continue a similar trend during the forecast period, followed by Europe. Regulatory practices of monocyte activation tests by organizations such as United States Pharmacopeia (USP) and the Government of Canada have further fueled the overall growth of the monocyte activation tests market in the region. Also, increasing focus on patient safety concerns and improved healthcare outcomes is one of the factors aiding the market growth in North America.

Merck KGaA, Darmstadt, Germany and/or its affiliates; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; Sanquin; and Lonza Group are among the leading companies operating in the monocyte activation tests market.

In October 2023, Lonza launched two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and ease rabbit-free pyrogen testing. The systems will replace Lonza’s traditional MAT system kit offerings, and the newly launched products contain the new PeliKine Human IL-6 Rapid ELISA Kit that minimizes hands-on time and reduces time-to-results from two days to two hours. The new tests give pharmaceutical and biotechnology manufacturers easier MAT testing options for product safety testing while helping to reduce the reliance on animals.